Keith J. Kendall
2019
In 2019, Keith J. Kendall earned a total compensation of $2.6M as Chief Executive Officer at Aquestive Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $288,924 |
|---|---|
| Option Awards | $1,768,598 |
| Salary | $540,385 |
| Other | $30,669 |
| Total | $2,628,576 |
Kendall received $1.8M in option awards, accounting for 67% of the total pay in 2019.
Kendall also received $288.9K in non-equity incentive plan, $540.4K in salary and $30.7K in other compensation.
Rankings
In 2019, Keith J. Kendall's compensation ranked 4,648th out of 13,971 executives tracked by ExecPay. In other words, Kendall earned more than 66.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,648 out of 13,971 | 67th |
Division Manufacturing | 1,736 out of 5,701 | 70th |
Major group Chemicals And Allied Products | 608 out of 2,200 | 72nd |
Industry group Drugs | 512 out of 1,886 | 73rd |
Industry Pharmaceutical Preparations | 385 out of 1,398 | 73rd |
Source: SEC filing on April 29, 2020.
Kendall's colleagues
We found two more compensation records of executives who worked with Keith J. Kendall at Aquestive Therapeutics in 2019.